| abstract |
The present invention relates to novel therapeutically active selective inhibitors of the enzyme dipeptidyl peptidase IV, pharmaceutical compositions comprising said compounds and type 2 diabetes mellitus, hyperglycemia, impaired glucose tolerance, metabolic syndrome (syndrome X) Or insulin resistance syndrome), grape diabetes, metabolic acidosis, cataract, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, type 1 diabetes, obesity, obesity-induced condition, hypertension , Hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, fragility, bone loss, fracture, acute coronary syndrome, infertility due to polycystic ovary syndrome, short bowel syndrome, anxiety, depression, insomnia, chronic Diseases with proteins treated by DPP-IV such as fatigue, epilepsy, eating disorders, chronic pain, drinking alcohol, bowel movement related diseases, ulcers, irritable bowel syndrome, inflammatory bowel syndrome To treat, and to the use of such compounds in order to prevent disease progression in type 2 diabetes. The invention further relates to a method of identifying an insulin secretagogue for diabetes. |